Trial Profile
A Phase II, Randomized-Controlled Trial of AST-OPC1 in Patients with Spinal Cord Injuries
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2019
Price :
$35
*
At a glance
- Drugs OPC 1 (Primary)
- Indications Spinal cord injuries
- Focus Therapeutic Use
- Sponsors Asterias Biotherapeutics; Lineage Cell Therapeutics
- 04 Sep 2019 According to an Lineage Cell Therapeutics media release, this study is expected to begin later in 2020.
- 31 Jul 2019 According to an BioTime media release, the company has changed its name to Lineage Cell Therapeutics, Inc.
- 24 Jan 2019 According to an Asterias Biotherapeutics media release, the Company held a Type B meeting with the Food and Drug Administration (FDA) late last year where FDA agreed with the companys plan to initiate this trial.